Data from the randomized, double-blind, placebo-controlled phase 3 NORA trial (NCT03705156) indicated that niraparib (Zejula) maintenance treatment reduced the risk of disease progression or death and prolonged progression-free survival (PFS) in Chinese patients with platinum-sensitive, recurrent ovarian cancer when compared with placebo.1
The study, published in Annals of Oncology, also indicated that an individualized starting dose (ISD) of niraparib based on baseline bodyweight and platelet count could improve the tolerability of niraparib without affecting treatment outcomes, and should therefore be considered standard practice in this patient setting.
“This is the first trial of PARP inhibitor maintenance therapy for ovarian cancer conducted in an Asian patient population and will support a change in clinical practice,” wrote the study authors, who were led by Xiaohua Wu, MD,…
